Mr. Miller was appointed as a director of Puma Biotechnology on February 23, 2018. Mr. Miller most recently served as the Executive Vice President U.S. Commercial of Jazz Pharmaceuticals plc, a public biopharmaceutical company, from April 2014 until his retirement in September 2020. Since July 2022, he currently serves as a member of the Board of Directors of BioXcel Therapeutics, Inc.
From April 2010 to January 2014, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus, Inc., a public biopharmaceutical company. From 2006 to 2010, Mr. Miller served as Vice President, Sales and Marketing, leading the HER Family Oncology Franchise, of Genentech, Inc., a biotechnology company and wholly owned subsidiary of Roche Holding Ltd. From 2003 to 2005, Mr. Miller served as the Senior Vice President, Chief Commercial Officer of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories, Inc. Previously, from 1997 to 2001, Mr. Miller served as Vice President of the Urology Business Unit of ALZA Corporation, a pharmaceutical company acquired by Johnson & Johnson. Prior to 1997, Mr. Miller served 13 years in various sales and marketing positions at Syntex Corporation, a pharmaceutical company acquired by Roche Holding Ltd. He also served as a member of non-profit boards, including the Leukemia and Lymphoma Society (Silicon Valley Chapter).
Mr. Miller received a B.S. in Business Administration and Finance from the University of San Francisco and an M.B.A. in Information and Computer Systems from San Francisco State University. Mr. Miller was selected as a director because of his significant experience and background in the life sciences industry.
What is Michael Patrick Miller's net worth?
The estimated net worth of Michael Patrick Miller is at least $409.86 thousand as of November 11th, 2025. Miller owns 54,000 shares of Puma Biotechnology stock worth more than $409,860 as of April 30th. This net worth approximation does not reflect any other investments that Miller may own. Learn More about Michael Patrick Miller's net worth.
How do I contact Michael Patrick Miller?
Has Michael Patrick Miller been buying or selling shares of Puma Biotechnology?
Michael Patrick Miller has not been actively trading shares of Puma Biotechnology in the last ninety days. Most recently, Michael Patrick Miller sold 20,000 shares of the business's stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $4.86, for a transaction totalling $97,200.00. Following the completion of the sale, the director now directly owns 54,000 shares of the company's stock, valued at $262,440. Learn More on Michael Patrick Miller's trading history.
Who are Puma Biotechnology's active insiders?
Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Michael Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 1/7/2026.
